References
1. Japan Pharmaceutical Manufacturers Association. Data Book 2021 Online2021 [updated March 11; cited 2022 March 2]. Available from: https://www.jpma.or.jp/news_room/issue/databook/2021_en/lofurc0000004we3-att/DB2021_en_full.pdf.
2. Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, et al. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016. Health Policy. 2020;124(7):727-35. Epub 2020/05/23. doi: 10.1016/j.healthpol.2020.03.011. PubMed PMID: 32439213.
3. Japan Pharmaceutical Manufacturers Association. Regarding the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions 2018 [cited 2022 March 4]. Available from: https://www.jpma.or.jp/english/code/transparency_guideline/eki4g60000003klk-att/transparency_gl_intro_2018.pdf.
4. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J. 2021;32(2):443-51. Epub 2020/11/06. doi: 10.1007/s00192-020-04547-3. PubMed PMID: 33151353.
5. Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS One. 2020;15(10):e0239610. Epub 2020/10/14. doi: 10.1371/journal.pone.0239610. PubMed PMID: 33048952; PubMed Central PMCID: PMCPMC7553305 Pharmaciez. Also Dr. Saito received personal fees from TAIHO Pharmaceutical Co., Ltd. outside the scope of the submitted work. Drs. Ozaki and Tanimoto received personal fees from Medical Network Systems outside the scope of the submitted work. This donation from Ain Pharmaceiz does not alter our adherence to PLoS ONE policies on sharing data and materials.
6. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg. 2021;0(0):1945998211034724. Epub 2021/08/18. doi: 10.1177/01945998211034724. PubMed PMID: 34399654.
7. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer Journal. 2022;12(4):54. doi: 10.1038/s41408-022-00656-y.
8. Ozaki A, Saito H, Onoue Y, Sawano T, Shimada Y, Somekawa Y, et al. Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open. 2019;9(9):e028805. Epub 2019/09/09. doi: 10.1136/bmjopen-2018-028805. PubMed PMID: 31494604; PubMed Central PMCID: PMCPMC6731803.
9. Rathi VK, Samuel AM, Mehra S. Industry ties in otolaryngology: initial insights from the physician payment sunshine act. Otolaryngol Head Neck Surg. 2015;152(6):993-9. Epub 2015/03/18. doi: 10.1177/0194599815573718. PubMed PMID: 25779469.
10. Morse E, Fujiwara RJT, Mehra S. Increasing Industry Involvement in Otolaryngology: Insights from 3 Years of the Open Payments Database. Otolaryngol Head Neck Surg. 2018;159(3):501-7. Epub 2018/05/29. doi: 10.1177/0194599818778502. PubMed PMID: 29807484.
11. Pathak N, Fujiwara RJT, Mehra S. Assessment of Nonresearch Industry Payments to Otolaryngologists in 2014 and 2015. Otolaryngology–Head and Neck Surgery. 2018;158(6):1028-34. doi: 10.1177/0194599818758661.
12. Morse E, Berson E, Mehra S. Industry Involvement in Otolaryngology: Updates from the 2017 Open Payments Database. Otolaryngol Head Neck Surg. 2019;161(2):265-70. Epub 2019/03/27. doi: 10.1177/0194599819838268. PubMed PMID: 30909808.
13. Brauer PR, Morse E, Mehra S. Industry Payments for Otolaryngology Research: A Four-Year Analysis of the Open Payments Database. Laryngoscope. 2020;130(2):314-20. Epub 2019/05/07. doi: 10.1002/lary.27896. PubMed PMID: 31059584.
14. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA. 2017;317(17):1774-84. Epub 2017/05/04. doi: 10.1001/jama.2017.3091. PubMed PMID: 28464140; PubMed Central PMCID: PMCPMC5470350.
15. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. Mayo Clin Proc. 2016;91(1):84-96. Epub 2016/01/15. doi: 10.1016/j.mayocp.2015.10.016. PubMed PMID: 26763512; PubMed Central PMCID: PMCPMC4739814.
16. Tierney NM, Saenz C, McHale M, Ward K, Plaxe S. Industry Payments to Obstetrician–Gynecologists: An Analysis of 2014 Open Payments Data. Obstetrics & Gynecology. 2016;127(2).
17. Maruf M, Sidana A, Fleischman W, Brancato SJ, Purnell S, Agrawal S, et al. Financial Relationships between Urologists and Industry: An Analysis of Open Payments Data. Urology Practice. 2018;5(3):180-6. doi: https://doi.org/10.1016/j.urpr.2017.03.012.
18. Gangireddy VGR, Amin R, Yu K, Kanneganti P, Talla S, Annapureddy A. Analysis of payments to GI physicians in the United States: Open payments data study. JGH Open. 2020;4(6):1031-6. doi: 10.1002/jgh3.12401. PubMed PMID: 33319034.
19. Heckmann ND, Mayfield CK, Chung BC, Christ AB, Lieberman JR. Industry Payment Trends to Orthopaedic Surgeons From 2014 to 2018: An Analysis of the First 5 Years of the Open Payments Database. J Am Acad Orthop Surg. 2022;30(2):e191-e8. Epub 2021/12/31. doi: 10.5435/jaaos-d-21-00412. PubMed PMID: 34967798.
20. Pakanati AR, Kovvuru K, Thombre V, Kanduri SR, Nalleballe K, Ranabothu S. Industry Payments to Nephrologists in the United States. Cureus. 2021;13(8):e17057. Epub 2021/09/16. doi: 10.7759/cureus.17057. PubMed PMID: 34522535; PubMed Central PMCID: PMCPMC8428165.
21. Putman MS, Goldsher JE, Crowson CS, Duarte-García A. Industry Payments to Practicing US Rheumatologists, 2014–2019. Arthritis & Rheumatology. 2021;73(11):2138-44. doi: https://doi.org/10.1002/art.41896.
22. Clinckemaillie M, Scanff A, Naudet F, Barbaroux A. Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study. BMJ Open. 2022;12(2):e051042. doi: 10.1136/bmjopen-2021-051042.
23. Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ. 2020;369:m1505. doi: 10.1136/bmj.m1505.
24. Karanges E, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. Australian Journal for General Practitioners. 2020;49:151-4.
25. Saito H, Ozaki A, Kobayashi Y, Sawano T, Tanimoto T. Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan. JAMA Intern Med. 2019;179(4):578-80. Epub 2019/02/05. doi: 10.1001/jamainternmed.2018.7283. PubMed PMID: 30715087; PubMed Central PMCID: PMCPMC6450293.
26. Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels. JAMA Netw Open. 2018;1(8):e186343. Epub 2019/01/16. doi: 10.1001/jamanetworkopen.2018.6343. PubMed PMID: 30646328; PubMed Central PMCID: PMCPMC6324539.
27. Sismondo S. Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won’t Cast Light on. The Journal of Law, Medicine & Ethics. 2013;41(3):635-43. doi: 10.1111/jlme.12073. PubMed PMID: 24088154.
28. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336(7658):1402-3. Epub 2008/06/21. doi: 10.1136/bmj.39575.675787.651. PubMed PMID: 18566074; PubMed Central PMCID: PMCPMC2432185.
29. Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et al. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. International Journal of Environmental Research and Public Health. 2022;19(12):7417. PubMed PMID: doi:10.3390/ijerph19127417.
30. Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clinical Journal of the American Society of Nephrology. 2022:CJN.14661121. doi: 10.2215/CJN.14661121.
31. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54. Epub 2022/04/09. doi: 10.1038/s41408-022-00656-y. PubMed PMID: 35393417; PubMed Central PMCID: PMCPMC8989935 Pharmaceutical Co., Ltd outside the scope of the submitted work. HS received personal fees from Taiho Pharmaceutical Co. Ltd outside the scope of the submitted work. AO and TT received personal fees from Medical Network Systems outside the scope of the submitted work. TT also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial competing interests among the study authors, all are engaged in ongoing research examining financial and non-financial competing interests among healthcare professionals and pharmaceutical companies in Japan. Individually, AM, SK, HS, TS, TT, and AO have contributed to several published studies assessing competing interests and quality of evidence among clinical practice guideline authors in Japan and the United States. Among their previous articles, the authors have self-cited several articles in this study to gain deeper insights and explain the context of financial competing interests among healthcare professionals in Japan. EK was a hematology specialist board-certified by the Japanese Society of Hematology. The other authors have no example competing interests to disclose.
32. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data. JAMA Dermatol. 2016;152(12):1307-13. Epub 2016/10/06. doi: 10.1001/jamadermatol.2016.3037. PubMed PMID: 27706478.
33. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP. Industry Payments to Cardiologists. Circulation: Cardiovascular Quality and Outcomes. 2018;11(12):e005016. doi: 10.1161/CIRCOUTCOMES.118.005016.
34. Murayama A, Hoshi M, Saito H, Kamamoto S, Tanaka M, Kawashima M, et al. Nature and Trends of Pharmaceutical Payments to Board Certificated Respiratory Specialists in Japan between 2016 and 2019. medRxiv. 2022:2022.01.16.22269188. doi: 10.1101/2022.01.16.22269188.
35. Cvetanovich GL, Chalmers PN, Bach BR, Jr. Industry Financial Relationships in Orthopaedic Surgery: Analysis of the Sunshine Act Open Payments Database and Comparison with Other Surgical Subspecialties. JBJS. 2015;97(15).
36. Morse E, Hanna J, Mehra S. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists. Otolaryngol Head Neck Surg. 2019;161(4):605-12. Epub 2019/09/25. doi: 10.1177/0194599819852321. PubMed PMID: 31547772.
37. Morse E, Fujiwara RJT, Mehra S. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids. Otolaryngol Head Neck Surg. 2018;159(3):442-8. Epub 2018/06/06. doi: 10.1177/0194599818774739. PubMed PMID: 29865931.
38. Gadkaree SK, Rathi VK, Gottschalk E, Feng AL, Phillips KM, Scangas GA, et al. The role of industry influence in sinus balloon dilation: Trends over time. The Laryngoscope. 2018;128(7):1540-5. doi: https://doi.org/10.1002/lary.27203.
39. Fujiwara RJT, Shih AF, Mehra S. Cross-sectional Analysis of the Relationship between Paranasal Sinus Balloon Catheter Dilations and Industry Payments among Otolaryngologists. Otolaryngol Head Neck Surg. 2017;157(5):880-6. Epub 2017/09/13. doi: 10.1177/0194599817728897. PubMed PMID: 28895455.
40. Duarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, et al. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clin Proc. 2022;97(2):250-60. Epub 2022/02/06. doi: 10.1016/j.mayocp.2021.08.026. PubMed PMID: 35120693; PubMed Central PMCID: PMCPMC9013005.
41. Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review. Ann Intern Med. 2021;174(3):353-61. Epub 2020/11/24. doi: 10.7326/M20-5665. PubMed PMID: 33226858; PubMed Central PMCID: PMCPMC8315858.
42. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, et al. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. Circulation: Cardiovascular Quality and Outcomes. 2021;14(5):e007521. doi: 10.1161/CIRCOUTCOMES.120.007521.
43. Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians. JAMA Internal Medicine. 2019;179(10):1424-5. doi: 10.1001/jamainternmed.2019.0999.
44. Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin. JAMA Network Open. 2018;1(2):e180482-e. doi: 10.1001/jamanetworkopen.2018.0482.
45. Eloy JA, Svider PF, Bobian M, Harvey RJ, Gray ST, Baredes S, et al. Industry relationships are associated with performing a greater number of sinus balloon dilation procedures. International Forum of Allergy & Rhinology. 2017;7(9):878-83. doi: https://doi.org/10.1002/alr.21976.
46. DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Internal Medicine. 2016;176(8):1114-22. doi: 10.1001/jamainternmed.2016.2765.
47. Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018;117:50-6. Epub 2018/04/24. doi: 10.1016/j.urology.2018.04.008. PubMed PMID: 29680480; PubMed Central PMCID: PMCPMC6005747.
48. Perlis RH, Perlis CS. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs. PLOS ONE. 2016;11(5):e0155474. doi: 10.1371/journal.pone.0155474.
49. Jastifer J, Roberts S. Patients’ Awareness of and Attitudes toward Gifts from Pharmaceutical Companies to Physicians. International Journal of Health Services. 2009;39(2):405-14. doi: 10.2190/HS.39.2.j.
50. Murayama A, Senoo Y, Harada K, Kotera Y, Saito H, Sawano T, et al. Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians. International Journal of Environmental Research and Public Health. 2022;19(6). doi: 10.3390/ijerph19063478.
51. Ammous A, Bou Zein Eddine S, Dani A, Dbaibou J, El-Asmar JM, Sadder L, et al. Awareness and attitudes of the Lebanese population with regard to physician-pharmaceutical company interaction: a survey study. BMJ Open. 2017;7(3):e013041. Epub 2017/04/02. doi: 10.1136/bmjopen-2016-013041. PubMed PMID: 28363922; PubMed Central PMCID: PMCPMC5387964.
52. Fadlallah R, Nas H, Naamani D, El-Jardali F, Hammoura I, Al-Khaled L, et al. Knowledge, Beliefs and Attitudes of Patients and the General Public towards the Interactions of Physicians with the Pharmaceutical and the Device Industry: A Systematic Review. PLOS ONE. 2016;11(8):e0160540. doi: 10.1371/journal.pone.0160540.
53. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992;102(1):270-3. Epub 1992/07/01. doi: 10.1378/chest.102.1.270. PubMed PMID: 1623766.
54. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010;7(10):e1000352. Epub 2010/10/27. doi: 10.1371/journal.pmed.1000352. PubMed PMID: 20976098; PubMed Central PMCID: PMCPMC2957394 BM, JL, NO, and AV are members of Healthy Skepticism Inc. Healthy Skepticism is an international nonprofit research, education, and advocacy association with the main aim of reducing harm from misleading health information. PRM is the director of Healthy Skepticism Inc., and is mostly unpaid. PRM’s wife and two of his daughters are part-time employees of Healthy Skepticism Inc. JL is a member of the management committee of Healthy Skepticism.
55. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of Recommendations. Hepatology. 2021;n/a(n/a). Epub 2021/12/03. doi: 10.1002/hep.32262. PubMed PMID: 34856007.
56. Chengappa M, Herrmann S, Poonacha T. Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines. Kidney International Reports. 2021;6(3):768-74. doi: 10.1016/j.ekir.2020.12.014.
57. Wayant C, Walters C, Zaaza Z, Gilstrap C, Combs T, Crow H, et al. Evaluation of Financial Conflicts of Interest Among Physician-Authors of American College of Rheumatology Clinical Practice Guidelines. Arthritis Rheumatol. 2020;72(9):1427-34. Epub 2020/02/11. doi: 10.1002/art.41224. PubMed PMID: 32039569.
58. Elder K, Turner KA, Cosgrove L, Lexchin J, Shnier A, Moore A, et al. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ. 2020;192(23):E617-E25. Epub 2020/06/17. doi: 10.1503/cmaj.191737. PubMed PMID: 32538799; PubMed Central PMCID: PMCPMC7867217 Canadian Task Force on Preventive Health Care (CTFPHC), which was the producer of one guideline included in the present study (cited as reference 41). Brett Thombs, Ainsley Moore and Sharon Straus are the chair, vice-chair and director of knowledge translation, respectively, for the CTFPHC. The present work was not commissioned or funded by the CTFPHC, and the authors participated in the study outside of their responsibilities with the CTFPHC. No other competing interests were declared.
59. Desai AP, Chengappa M, Go RS, Poonacha TK. Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. Cancer. 2020;126(16):3742-9. Epub 2020/06/05. doi: 10.1002/cncr.32997. PubMed PMID: 32497271.
60. Wong VSS, Avalos LN, Callaham ML. Industry payments to physician journal editors. PLOS ONE. 2019;14(2):e0211495. doi: 10.1371/journal.pone.0211495.
61. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ. 2017;359:j4619. Epub 2017/10/28. doi: 10.1136/bmj.j4619. PubMed PMID: 29074628; PubMed Central PMCID: PMCPMC5655612 (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
62. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, et al. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open. 2019;9(2):e025864. Epub 2019/03/01. doi: 10.1136/bmjopen-2018-025864. PubMed PMID: 30813119; PubMed Central PMCID: PMCPMC6377504.
63. Taheri C, Kirubarajan A, Li X, Lam ACL, Taheri S, Olivieri NF. Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review. BMJ Open. 2021;11(4):e045306. doi: 10.1136/bmjopen-2020-045306.
64. Bansal R, Khan R, Scaffidi MA, Gimpaya N, Genis S, Bukhari A, et al. Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States. Gastrointest Endosc. 2020;91(2):266-73. Epub 2019/11/19. doi: 10.1016/j.gie.2019.11.010. PubMed PMID: 31738925.
65. Saleh RR, Majeed H, Tibau A, Booth CM, Amir E. Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. Cancer. 2019;125(22):4069-75. Epub 2019/07/30. doi: 10.1002/cncr.32408. PubMed PMID: 31355923.
66. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med. 2015;163(7):548-53. Epub 2015/10/06. doi: 10.7326/M14-1885. PubMed PMID: 26436619.
67. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors. Washington, DC: The National Academies Press; 2011. 290 p.
68. Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest policies among organizations producing clinical practice guidelines. PLOS ONE. 2021;16(4):e0249267. doi: 10.1371/journal.pone.0249267.